Sofinnova
Sofinnova is a leading healthcare investment firm with a focus on life sciences, particularly therapeutic drugs. Founded in 1976, the firm has a strong track record of investing in transformative therapies, guiding companies from drug development through regulatory processes to IPOs. With approximately $3.3 billion in assets under management, Sofinnova partners with entrepreneurs to improve patient lives through science, leveraging deep industry knowledge and extensive experience in both private and public equity markets.
Sofinnova
3000 Sand Hill Road, Building 3-Suite 150, Menlo Park, CA 94025
What We Do
Sofinnova provides financial capital to life science companies, helping them turn innovative ideas into market-ready drugs.
The firm offers strategic guidance and mentorship to entrepreneurs, helping them navigate the complexities of drug development and regulatory processes.
Sofinnova assists companies in building their operations and preparing for IPOs, ensuring they are well-positioned for public markets.
The firm provides operational support and networking opportunities to its portfolio companies, connecting them with industry experts and potential partners.
Industry Focus
Show More (2)Investment Range
Portfolio
Received FDA Fast Track Designation for CUSP06 for the treatment of platinum-resistant ovarian cancer.
#Biotechnology
Acquired global rights to a novel, next-generation dual BAFF/APRIL inhibitor.
#Biotechnology
Announced new Phase 1 data supporting RAP-219’s transformative potential for CNS disorders.
#Biotechnology
Key People
Managing Partner
General Partner
Executive Partner, Private Equity
Executive Partner, Private Equity
Executive Advisor, Private Equity
Senior Analyst